Roche Holding Ltd · SIX:RO
Roche — BofA Global HC Conference 2024
14 slides from Roche's conference presentation, Sep 18, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Bruno Eschli | Head IR Roche Group BofA Global HC Conference London, 18 September 2024
Slide 4: Performance
Performance Outlook
Slide 5: HY 2024: High single digit growth in both divisions in Q2
HY 2024: High single digit growth in both divisions in Q2 Second quarter without significant COVID-19 impact Pharma* Diagnostics* Quarterly sales evolution 2022-2024 Quarterly sales evolution 2022-2024 % CER % CER 30% 30% +24% 20% 20% +12% +9% +10% +8% +9% 10% +6% +9% +7% +7% +7% +9% 10% +7% +8% +8%
Slide 6: HY 2024: Young portfolio delivering strong growth
HY 2024: Young portfolio delivering strong growth Vabysmo and Phesgo excellent growth momentum continues; Polivy on-track for blockbuster status Vabysmo 93% Phesgo 60% Ocrevus 8% Polivy 54% Evrysdi 25% Hemlibra 7% Xolair 10% Columvi >500% Gazyva 15% Alecensa 7% Xofluza 183% Actemra / RoActemra 3% En
Slide 7: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 2024 NME update: US approval for PiaSky in PNH achieved; inavolisib in HR+ breast cancer with PDUFA 27 Nov CHFm % of Pharma Sales2 14.0 55% 12.0 50% 10.0 41% 8.0 33% 6.0 1 4.0 2.0 0.0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 HY 2021 H
Slide 8: HY 2024: Group core operating performance
HY 2024: Group core operating performance Core operating profit higher by +11% driven by higher sales and effective cost management HY 2024 HY 2024 vs. HY 2023 CHFm abs. CER CER growth Sales 29,848 +1,515 5% Other revenue 908 +94 11% Cost of sales -7,300 -168 2% R&D -6,268 -21 0% SG&A -6,376 -96 2%
Slide 9: 2024 outlook confirmed
2024 outlook confirmed Group sales growth1 Mid single digit sales growth Broadly in line with sales growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Further increase dividend in Swiss francs 1At Constant Exchange Rates (CER) 9
Slide 10: Outlook
Performance Outlook
Slide 11: Key growth drivers beyond 2025
Key growth drivers beyond 2025 Many opportunities with significant market potential in both divisions Pharmaceuticals Diagnostics NME Indication Newsflow Timing Product Description Launch tiragolumab NSCLC Final Ph III data H2 2024 Total solution for clinical mass i601 mass spec 2024 spectrometry an
Slide 12: Upcoming Roche IR events 2024
Upcoming Roche IR events 2024 Additional events driven by readouts CVM/EASD Pharma Day Neurology/CTAD Digitalization Day Sep 13 Sep 30 Oct/Nov Nov • Key data presented at EASD: • Group & Pharma strategy • Key data presented at CTAD: • Roche digital efforts in Pharma • CT-388 (Ph I cohort 11 & 12 in
Slide 13: Progress on key strategic initiatives
Progress on key strategic initiatives Updated Group and Pharma strategies to be presented at Pharma Day on September 30th 2023 2024 Milestones achieved Q2 Q3 Q4 Q1 Q2 Q3 Q4 • Revised Ten-Year Ambitions and Group Strategy Group Presentation @ • New performance and reward practices rolled out Pharma D
Slide 14: Doing now what patients need next
Doing now what patients need next